Eupraxia Pharmaceuticals (EPRX) Net Income (2023 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 4 years of Net Income data on file, last reported at -$12.7 million in Q1 2026.

• On a quarterly basis, Net Income fell 87.0% year-over-year to -$12.7 million in Q1 2026; TTM through Mar 2026 was $16.0 million, a 9.12% decrease from a year earlier, with the FY2025 full-year figure at -$38.6 million, down 49.96% from the prior year.
• Net Income for Q1 2026 stood at -$12.7 million, down from $37.4 million in the prior quarter.
• Over the last five years, Net Income for EPRX reached as high as $37.4 million in Q3 2025 and fell as low as -$17.4 million in Q2 2023.
• Historically, Net Income has averaged $4.6 million across 4 years, with a median of -$1.1 million in 2023.
• Across the five-year window, Net Income sank 255.63% in 2024 and jumped 524.22% in 2025, its largest moves.
• Year by year, Net Income stood at $31.8 million in 2023, then sank by 81.17% to $6.0 million in 2024, then soared by 524.22% to $37.4 million in 2025, then tumbled by 133.84% to -$12.7 million in 2026.
• Per Business Quant data, the three most recent Net Income figures were -$12.7 million in Q1 2026, $37.4 million in Q3 2025, and -$8.7 million in Q2 2025.